Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 1999

View Archived Issues

First human trial of Sheffield's pulmonary delivery system for migraine therapy

CV Therapeutics receives SBIR grant to study effects of adenosine in angiogenesis

Bayer to divest Troponwerke division

German launch and local distributor announced for Tanabe's ACE inhibitor

SK-951 demonstrates advantages over cisapride in models of impaired gastric emptying

Positive preliminary results achieved in phase III anti-IgE asthma study

Licensing opportunity from NIH: orally active neuron cell death-inhibitory peptides

Schwarz sells intranasal scopolamine rights to Nastech

Oxford Asymmetry achieves first milestone in collaboration with Ontogeny

FDA approves topical treatment for nail fungus

Sankyo to turn joint venture into subsidiary to market products in U.S.

AstraZeneca discovers new cytokine inhibitors acting as p38 MAP kinase inhibitors

Inhibitors of PARP activity continue to emerge from Guilford R&D

Banyu isolates novel antifungal substance BE-54753

New cardiovascular agents from Yamanouchi

Efficacy and mechanism of action of DX-9065a in experimental DIC in rats

Japanese launch announced for Actos; other antidiabetic agents in the pipeline

Hungarian team describes novel orally active antithrombotic agents

Parke-Davis identifies atypical antipsychotic with clinical potential

Orally active antiplatelet agents derived from isoquinolone leads at Lilly

Discovery of potent FTase inhibitors with excellent cellular and in vivo activity reported by Abbott

Milestone for Gene Logic in kidney disease collaboration

Allergan expands ophthalmic allergy product portfolio

AstraZeneca commences phase II monotherapy trials of ZD-0473

GRF analogue expected to proceed to phase II trials in 2000

Neose Technologies discontinues development of NE-1530

Anti-CD11a enters phase III for psoriasis

Bristol-Myers Squibb seeks regulatory approvals worldwide for Vanlev

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...